ClinicalTrials.gg
RecruitingNCT07895628Updated Nov 12, 2026

A Crossover Study Evaluating the Postprandial Glycemic Response of Three Sweeteners in a Mixed Meal Setting

An interventional study of LOAM Fiber-based Sweetener and Sugar in Postprandial Glucose and GI Tolerance, sponsored by LOAM Science. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by LOAM Science · Not applicable, Interventional, and Basic science

How we know

Updated Nov 12, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is using a double-blind, randomize crossover evaluating the impact of three different sweeteners on postprandial glycemic response in a mixed meal setting. In 50 individuals, postprandial glucose response will be evaluated as a primary objective. Secondary objectives include additional measures of glucose response as well general gastrointestinal response to the sweeteners, assessed through a series of questionnaires.

02

Conditions studied

  • Postprandial Glucose
  • GI Tolerance

Keywords

  • Fiber
  • Postprandial Glucose Response
  • Sweetener
03

In context

Lead sponsor

LOAM Science is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18 or older
  • between 18.5 and 29.9 kg/m2, inclusive, based on self-reported height and weight.
  • Self-reported general good health, without a diagnosis of diabetes or prediabetes.
  • Willing and able to consume the standardized study breakfast, consisting of a plain bagel with plain cream cheese, on six specified mornings.
  • Willing to wear a continuous glucose monitor continuously on the upper arm for approximately 10 consecutive days.
  • Willing to observe an overnight fast of at least 8 hours before each test morning and to follow test-day standardization instructions.
  • Owns a compatible smartphone with reliable internet access and is willing to install the required study and sensor applications.
  • Resides in the United States and is able to receive shipments at a residential address.
  • Able to read, understand, and communicate in English.
  • Willing and able to provide electronic through a digital platform.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of type 1 diabetes, type 2 diabetes, prediabetes, or a history of gestational diabetes.
  • Current use of any glucose-lowering medication, including insulin, metformin, sulfonylureas, GLP-1 receptor agonists, DPP-4 inhibitors, or SGLT2 inhibitors.
  • Current or recent use, within 30 days of consent, of systemic or any other medication known to materially alter glucose metabolism.
  • Celiac disease, wheat or gluten allergy or intolerance, or any dairy allergy or lactose intolerance that would preclude consumption of the standardized study breakfast or exclusion of gluten or dairy from the diet for any other reason that would preclude consumption of the standardized breakfast.
  • Known allergy or sensitivity to steviol glycosides, sucrose, or any declared component of the study preloads.
  • Known adhesive allergy or history of significant skin reaction to wearable sensors or medical adhesives.
  • Diagnosed gastrointestinal condition affecting digestion or absorption, including inflammatory bowel disease, gastroparesis, or prior bariatric or major gastrointestinal surgery.
  • Current eating disorder, or a diagnosed eating disorder within the previous 12 months.
  • Pregnant, breastfeeding, or planning to become pregnant during the study period.
  • Regular night-shift work, or planned travel across more than two time zones during the study period.
  • Planned substantial change in diet, physical activity, or body weight during the study period.
  • Current alcohol use disorder or substance use disorder.
  • Participation in another interventional research study within 30 days of consent or concurrently with this study.
  • Any condition or circumstance that, in the judgment of the Principal Investigator, would compromise participant safety or the integrity of the study data.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Sequence 1

    Sugar, stevia, and a fiber-based alternative sweetener will be evaluated in a pre-defined order.

    Dietary Supplement: LOAM Fiber-based Sweetener · Other: Sugar · Other: Stevia

  • Experimental
    Sequence 2

    Sugar, stevia, and a fiber-based alternative sweetener will be evaluated in a pre-defined order.

    Dietary Supplement: LOAM Fiber-based Sweetener · Other: Sugar · Other: Stevia

  • Experimental
    Sequence 3

    Sugar, stevia, and a fiber-based alternative sweetener will be evaluated in a pre-defined order.

    Dietary Supplement: LOAM Fiber-based Sweetener · Other: Sugar · Other: Stevia

  • Experimental
    Sequence 4

    Sugar, stevia, and a fiber-based alternative sweetener will be evaluated in a pre-defined order.

    Dietary Supplement: LOAM Fiber-based Sweetener · Other: Sugar · Other: Stevia

  • Experimental
    Sequence 5

    Sugar, stevia, and a fiber-based alternative sweetener will be evaluated in a pre-defined order.

    Dietary Supplement: LOAM Fiber-based Sweetener · Other: Sugar · Other: Stevia

  • Experimental
    Sequence 6

    Sugar, stevia, and a fiber-based alternative sweetener will be evaluated in a pre-defined order.

    Dietary Supplement: LOAM Fiber-based Sweetener · Other: Sugar · Other: Stevia

Interventions

  • Dietary supplementLOAM Fiber-based Sweetener

    A fiber-based sweetener produced by LOAM.

  • OtherSugar

    Table sugar

  • OtherStevia

    Stevia

06

What researchers measure

Primary outcomes

  1. Postprandial Area Under the Curve to 120 Minutes

    Area under the curve above baseline from time zero (the start of the preload consumption) through 120 minutes. Baseline is defined as the mean glucose over the 15 minutes prior to the preload consumption. Area falling below baseline will be excluded.

    Time frame: Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10.

Secondary outcomes

  1. Postprandial Area Under the Curve to 180 Minutes

    Area under the curve above baseline from time zero (the start of the preload consumption) through 180 minutes. Baseline is defined as the mean glucose over the 15 minutes prior to the preload consumption. Area falling below baseline will be excluded.

    Time frame: Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10.

  2. Postprandial Area Under the Curve to 120 Minutes Relative to Start of the Meal

    Area under the curve above baseline from time zero (the start of the meal consumption) through 120 minutes. Baseline is defined as the mean glucose over the 15 minutes prior to the preload consumption. Area falling below baseline will be excluded.

    Time frame: Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10.

  3. Peak Glucose

    Maximum observed glucose peak over the course of the 180 minute window.

    Time frame: Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10.

  4. Incremental Peak Glucose

    Maximum observed glucose peak relative to baseline over the course of the 180 minute window.

    Time frame: Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10.

  5. Time to Peak

    Elapsed time from preload consumption to the maximum observed value.

    Time frame: Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10.

  6. Post-Meal Subjective State

    Fullness, hunger, energy, and gastrointestinal comfort on a 0-10 numerical rating scale with 10 being an optimal situation and 0 representing the inverse for fullness, energy, and gastrointestinal comfort and 0 being an optimal situation and 10 representing the inverse for hunger. Questions are asked 60 and 180 minutes after the start of the mixed meal.

    Time frame: Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — IPD is proprietary information.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2026 (actual). Primary completion is estimated for Jan 2027, 2 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Dec 2026 → Nov 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2026
First posted
Oct 26, 2026
StartActual
Nov 9, 2026was Dec 2026
Primary completionEst.
Jan 15, 2027
CompletionEst.
May 1, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
1 site added — first site in United States
Show site
  • Alethios · San Francisco, United States
Nov 12, 2026
Start date
Dec 1, 2026→Nov 9, 2026 (actual)
Nov 12, 2026
Registered
First appeared on the registry
Oct 26, 2026
Show all 2 updates
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Alethios · San Francisco, United States
    Start date Dec 1, 2026→Nov 9, 2026 (now actual)
  2. Oct 26, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07895628
Lead sponsor
LOAM Science
Collaborators
Alethios, Inc.
Responsible party
Sponsor
First posted
Oct 26, 2026
Start date
Nov 9, 2026
Primary completion
Jan 15, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

John B Jarman, PhD
Contact
bryce@loamscience.com
323-325-1327

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion